Case Type: Mergers & Acquisitions

Global Net Lease, Inc. (NYSE: GNL) related to its merger with Modiv Industrial, Inc. Under the terms of the proposed transaction, Modiv Industrial shareholders are expected to own approximately 11% of the combined company.

Modiv Industrial, Inc. (NYSE: MDV) related to its sale to Global Net Lease, Inc. Under the terms of the proposed transaction, Modiv Industrial shareholders are expected to own approximately 11% of the combined company.

Esperion Therapeutics, Inc. (NASDAQ: ESPR) related to its sale to funds managed by ARCHIMED. Under the terms of the proposed transaction, Esperion shareholders are expected to receive $3.16 per share in cash and the right to participate in contingent milestone payments.

Pacific Financial Corporation (OTCQX: PFLC) related to its merger with Banner Corporation. Under the terms of the proposed transaction, Pacific Financial shareholders are expected to receive 0.2633 share of Banner common stock for each share of Pacific Financial.

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) related to its sale to Chiesi Group. Under the terms of the proposed transaction, KalVista shareholders are expected to receive $27.00 per share in cash.

BNCCORP, Inc. (OTCQX: BNCC) related to its sale to OppFi, Inc. Under the terms of the proposed transaction, BNCCORP shareholders are expected to receive (i) $19.375 in cash and (ii) a number of shares of Class A common stock of OppFi equal to an exchange ratio of 1.90 shares of Class A common stock for each BNCCORP … Read more

RE/MAX Holdings, Inc. (NYSE: RMAX) related to its sale to The Real Brokerage Inc. Under the terms of the proposed transaction, RE/MAX shareholders are expected to receive either 5.152 shares of the combined company or $13.80 in cash per share.

XOMA Royalty Corporation (NASDAQ: XOMA) related to its sale to Ligand Pharmaceuticals Incorporated. Under the terms of the proposed transaction, XOMA shareholders will receive $39.00 per share in cash.

Miluna Acquisition Corp. (NASDAQ: MMTX) related to its merger with CADV Ventures S.A.

Organon & Co. (NYSE: OGN)  related to its sale to Sun Pharmaceuticals Industries Limited. Under the terms of the proposed transaction, Organon shareholders will receive $14.00 per share in cash.